Compare BIAF & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIAF | CPHI |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 6.1M |
| IPO Year | 2022 | N/A |
| Metric | BIAF | CPHI |
|---|---|---|
| Price | $1.04 | $0.63 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 143.3K | 77.6K |
| Earning Date | 03-30-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,776,739.00 | $4,052,266.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $0.61 |
| 52 Week High | $46.53 | $3.18 |
| Indicator | BIAF | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 25.59 |
| Support Level | $0.69 | $0.61 |
| Resistance Level | $1.17 | $0.75 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 64.29 | 7.37 |
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.